Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors

Alberto Farolfi, Elisabetta Melegari, Michele Aquilina, Emanuela Scarpi, Toni Ibrahim, Roberta Maltoni, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Cristiano Ferrario, Anna Fedeli, Marina Faedi, Oriana Nanni, Giovanni Luca Frassineti, Dino Amadori, Andrea Rocca

Research output: Contribution to journalArticle

Abstract

Objective: Although adjuvant trastuzumab improves survival in patients with HER2-positive early breast cancer, there is growing concern about the long-term effect of trastuzumab-induced cardiotoxicity (TIC). We retrospectively assessed the incidence of TIC and heart failure (HF) to identify possible risk and protective factors. Design: Retrospective study. Setting: Institute for Cancer Research and Treatment, Medical: Oncology Department. Patients: Consecutive patients who started adjuvant trastuzumab between 2007 and 2010. Main outcome: Measures TIC was defined as an absolute left ventricular ejection fraction (LVEF) decrease ≥15 points from baseline or a LVEF2 of doxorubicin or >500 mg/m2 of epirubicin increased the risk of TIC compared with lower doses (OR 3.07;95% CI 1.29 to 7.27, p=0.0011). Conclusions: TIC is a frequent, albeit generally mild, adverse event in clinical practice. Further studies are warranted to better define the risk of and protective factors for TIC.

Original languageEnglish
Pages (from-to)634-639
Number of pages6
JournalHeart
Volume99
Issue number9
DOIs
Publication statusPublished - May 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors'. Together they form a unique fingerprint.

  • Cite this